Company
Hucord for the benefit of mankind
Global leader of cord blood stem cell applications
based on humanism and technology
Hucord Co.,Ltd. concentrates on the development of advanced technology of cord blood,
which is seen as “Drug repository of 21st ”, and stem cells
Company
Hucord for the benefit of mankind
Global leader of cord blood stem cell applications based on humanism and technology
Hucord Co.,Ltd. concentrates on the development of advanced technology of cord blood, which is seen
as “Drug repository of 21st ”, and stem cells
Company
Hucord for the benefit of mankind
Featured in the prestigious Nature magazine as the world’s
one of six stem cell treatment companies
in 2003, successfully isolated stem cells from cord blood for the first time in the world.
Hucord Co.,Ltd. possesses more than
10 original technology patents related to cord blood and cord blood stem cells, including cord blood cryopreservation, cord blood stem cell isolation
and culture, mixture method of mixed cord blood and peripheral blood without immune reaction and so on. In addition, Hucord Co.,Ltd.
published several papers with the results of clinical applications of cord blood stem cells in Buerger’s disease, liver cirrhosis etc.
Therefore, the technology and competitiveness acknowledged by international journal “Nature” and selected as Top 6 stem cell companies in the world.
Company
Hucord for the benefit of mankind
Featured in the prestigious Nature magazine as the world’s
one of six stem cell treatment companies
in 2003, successfully isolated stem cells from cord blood for the first time in the world.
Hucord Co.,Ltd. possesses more than 10 original technology patents related to cord blood and cord blood stem cells, including cord blood cryopreservation, cord blood stem cell isolation and culture, mixture method of mixed cord blood and peripheral blood without immune reaction and so on. In addition, Hucord Co.,Ltd. published several papers with the results of clinical applications of cord blood stem cells in Buerger’s disease, liver cirrhosis etc. Therefore, the technology and competitiveness acknowledged by international journal “Nature” and selected as Top 6 stem cell companies in the world.
History
Hucord’s challenge and innovation
-
2000
Establishment of Histostem.
Information on human umbilical
cord blood hematopoietic stem
cell disclosed to the public
for the first time
-
2001
World’s first to discover the
existence of stem cells in human
umbilical cord blood and
differentiation into osteoblast.
First cord blood bank in Korea to
provide human umbilical cord
blood to a foreign (Japanese)
patient.
-
2002
Became the first and only cord
blood bank in Korea
to be granted international
certification from AsiaCord.
-
2003
Succeeded in developing
the technology for separation
and cultivation of mesenchymal stem cells from cord blood.
Succeeded in proliferation and
differentiation of multipotent cells
of human cord blood.
Official announcement of the
treatment results of liver cirrhosis.
-
2004
Successfully performed
treatment in cerebral
infarction, spinal palsy,
Type II diabetes, multiple
sclerosis, burger disease,
cirrhosis, osteoporosis,
primary biliary cirrhosis
and hypertension.
-
2005
Treated an American
patient suffering from
spinal paralysis using
cord blood stem cells.
Transfused human
umbilical cord blood for
anemia patient in the
University of California,
San Francisco.
-
2006
36 emergency
clinical trial results in
animal experiments
such as spinal
paralysis.
-
2007
Gained authoritative
interpretation from the
Ministry of Food and
Drug Safety on cord
blood stem cell treatment
-
2008
Treated over 500
incurable diseases
-
2009
Succeeded in treating a
stroke patient who had
no chance of revival.
Developed human stem
cell conditioned media
(HSCM).
-
2010
Selected as the research
institue of WPM project
supported by the Ministry
of Knowledge Economy
with a grant of 1.25
million dollars.
-
2011
Published a paper using the
results from the preclinical trial of
spinal paralysis treatment with
human cord blood stem cells
(J Neurological Science).
Collected world’s largest amount
of 90,000 cord blood units.
-
2014
Changed the company name to
Hucord Co.,Ltd. and moved the
headquarters to Bundang Gu,
Seongnam City, Gyeonggi Do.
-
2015
Established a Hucord branch
subsidiary in Hanoi, Vietnam.
Released stem cell conditioned
media cosmetics ‘Babycell Cream’,
‘Babycell Serum’ and ‘HSCM’.
-
2016
Signed MOU with Vietnam 108
Military Central Hospital.
Lectured in Vietnam 108
Military Central Hospital in their
60th year science seminar.
Released stem cell conditioned
media product ‘HSCM100SF’.
Lectured in Japan JAAP 2016
conference seminar.
-
2017
Lectured in Cord Blood World
Europe 2017 conference that
took place in London, United
Kingdom.
Lectured in Japan JAAP
2017 conference seminar.
-
2018
Established a joint venture
‘Hucord-Vina’ in Hanoi, Vietnam.
Released a stem cell
conditioned media product
‘MORAN’.
-
2019
Released a stem cell
conditioned media cosmetics
product ‘HK0126’.
Obtained a product license in
Vietnam for ‘HSCM100’ and
‘MORAN’.
Began exporting HSCM
to the USA and Japan.
Established a joint venture
with a Chinese government
agency ‘MTP’.
-
2020
Obtained CFDA license
in China for ‘MORAN’
and ‘HK0126’.
Released a stem cell
conditioned media cosmetics
product, ‘INCORD’.
CI
Corporate Identity
-
Stem cells
생명,건강
-
-
Humanism
휴머니즘
-
-
Cord blood
제대혈
Hucord’s CI means the professional medical service for happy and healthy life based on humanism.
Social Contribution
treatment of incurable and rare diseases
best to provide good quality cord blood
Hucord Co.,Ltd. is trying best to provide good quality cord blood
to patients suffered from intractable diseases like leukemia. And lead
public services by making connections with public welfare
foundations to provide cord blood to 200 blood cancer patients
without charge and free subscriptions to low-income families and multicultural families.
Social Contribution
treatment of incurable and rare diseases
best to provide good quality cord blood
Hucord Co.,Ltd. is trying best to provide good quality cord blood
to patients suffered from intractable diseases like leukemia. And lead
public services by making connections with public welfare
foundations to provide cord blood to 200 blood cancer patients
without charge and free subscriptions to low-income families and multicultural families.
Direction
-
-
35-3, Soetgol-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, Republic of Korea
